PDGFRB and neoplasm: Lenvatinib is a pan-tyrosine kinase inhibitor, aimed at multiple targets, such as VEGFR-2, fibroblast growth factor receptor (FGFR), and PDGFR, which inhibits endothelial cell growth, crucial for supplying blood to tumor cells [17].